Amarillo Biosciences Teams with Animal Shelters to Improve Health and Enhance Immunity of Cats and Dogs

Amarillo, Texas, October 5, 2011 — Amarillo Biosciences, Inc. (ABI) (OTCBB: AMAR) today announced a program to provide a number of animal shelters with its new dietary supplement containing bovine protein extract, which has been shown to improve health and enhance immunity in animals and people. Because animal shelters co-mingle so many dogs and cats daily, they struggle to control viral respiratory infections as well as diarrhea and intestinal infections.  Products that can reduce the disease burden of the shelter population and relieve the need to euthanize pets are urgently needed. “As a veterinarian, I am eager to improve the health of animals in shelters both to help reduce operating expenses and provide healthier pets for adoption. We expect our branded dietary supplement to be on store shelves starting in the fourth quarter of 2011,” said Joseph Cummins, President & CEO of ABI. In the meantime, ABI is providing its dietary supplement at reduced cost to several animal shelters to demonstrate the benefits of the product.

 

About Amarillo Biosciences

Amarillo Biosciences, Inc. is a U.S. biotechnology firm operating in global partnership with the Hayashibara Group, which also holds 6% of Amarillo Biosciences shares and has provided over $18 million in loans, grants and equity investments. The Company's primary focus is extensive and ongoing R&D into the use of low-dose, orally administered interferon as a treatment for a variety of conditions, including influenza and hepatitis C. The Company has invested nearly $40 million to establish oral interferon as a therapeutic agent. The majority of those funds were invested in clinical trials in an effort to achieve FDA approval for interferon. Additional information is available on the web at http://www.amarbio.com.  Except for the historical information contained herein, the matters discussed in this news release are forward-looking statements that involve risks and uncertainties, including uncertainties related to product development, uncertainties related to the need for regulatory and other government approvals, dependence on proprietary technology, uncertainty of market acceptance of oral interferon or the Company’s other product candidates and other risks detailed from time to time in the Company’s filings with the Securities and Exchange Commission. In particular, see “Item 1. Description of Business” and “Item 7A. Qualitative and Quantitative Disclosures about Market Risk” of the Company’s Form 10-K for the fiscal year ended December 31, 2010.  --END--

 

Copyright © 2017 Amarillo Biosciences. All Rights Reserved.
Built and hosted by Dark Roast Hosting